ONCOLOGY Staff

Thought leaders Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, joined CancerNetwork® following the 2022 Genitourinary Cancers Symposium to discuss highlights of the meeting in a game show–style production.

Shilpa Gupta, MD, and Jason R. Brown, MD, PhD, discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Suzanne Fanning, DO, and Joshua Richter, MD, discuss clinical implications of a real-world study of ixazomib, lenalidomide, and dexamethasone compared with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the manuscript titled, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler and colleagues.

Neeraj Agarwal, MD, and Simon Chowdhury, MD, review final results from the TITAN study of apalutamide in patients with mCSPC and discuss the clinical implications of the findings.

Experts provide their recommendations for navigating a large and continuously growing treatment landscape, selecting between regimens, and monitoring patients with transplant-ineligible multiple myeloma.

In this program Atish D. Choudhury, MD, PhD, discusses recent updates on long-term safety and efficacy data in patients with metastatic castration-sensitive prostate cancer and the importance of patient communication and quality of life while on treatment.

John Mascarenhas, MD, hosts a panel of experts who discusses current strategies used to stratify risk patients with myelofibrosis and their preferences for sequencing therapy.

A panel of experts led by Sara Hurvitz, MD, discuss recent data within the HER2-positive breast cancer treatment landscape.

Alicia Morgans, MD, discusses genomic testing and use of PARP inhibitors for metastatic castration-resistant prostate cancer.

John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.

Experts in prostate cancer discuss recent advances in the treatment of patients with metastatic castration-naive and metastatic castration-resistant prostate cancer and strategies for optimizing therapy.

Expert panelists follow a patient case to discuss locally advanced and metastatic urothelial carcinoma with a focus on frontline and maintenance therapy.

ONCOLOGY® recaps an Around the Practice program moderated by Sagar Lonial, MD, with additional panelists Morie A. Gertz, MD; Parameswaran Hari, MD, MS; and Andrzej Jakubowiak, MD, PhD.

A panel of experts reflect on how to treat patients with advanced renal cell carcinoma by reviewing clinical trial data and discussing patient cases.

Recommendations for treating patients with steroid-refractory chronic GVHD based on evidence demonstrated by the REACH3 trial.

A panel of experts discuss strategies for optimizing first-line therapy for transplant-ineligible patients with newly diagnosed multiple myeloma.

As always, keep up with the latest issue of ONCOLOGY® to stay up-to-date on the latest practical and timely clinical information necessary to deliver the highest level of patient care.

The International Society of Gastrointestinal Oncology (ISGIO), hosted by Physicians’ Education Resource, LLC (PER®) presented the latest advances in the field of gastrointestinal cancer research.

Cesar A. Perez, MD, and Victoria M. Villaflor, MD, discuss tipifarnib in patients with head and neck cancers harboring HRAS mutations.

Brian T. Helfand, MD, PhD, and Steven E. Finkelstein, MD, discuss the potential of 18F-fluciclovine PET/CT to guide prostate cancer decision-making.

“We’ve been spoiled by 2 extraordinary experiences [in this setting]. Both tucatinib and trastuzumab deruxtecan are much better than anything we’ve had since we got pertuzumab for first-line therapy.” —SARA A. HURVITZ, MD, FACP

In this CancerNetwork® OncView™ program, faculty panelist Connie Batlevi, MD, PhD, explains the treatment options in this disease space and discusses a recent drug approval.

“We’re learning to understand how to leverage immunotherapy for a cure.”

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase 3 Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination vs Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability–High (MSI-H) Metastatic Colorectal Cancer (NCT02997228).

“These are priceless accomplishments that impact the lives of people.”

Kelly Valla, PharmD, BCOP, reviews the product profile of tazemetostat for the treatment of follicular lymphoma.